Subcutaneous autoinjector clinical and practical-use data for an Alzheimer's therapy are previewed, inviting readers to consider patient-focused implications.
Key Takeaways
- Once-weekly 500 mg subcutaneous dosing achieved drug exposure comparable to IV initiation
- Amyloid PET reduction, CDR-SB efficacy, and ARIA-E incidence depended on exposure, not administration route
- Real-world data from two US centers showed slower CDR-SB decline over 36 months versus ADNI